MEHLMAN CONSULTING, INC.

Lobbying for ULTRAGENYX PHARMACEUTICAL, INC. · Biopharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $60,000.00 income · posted Jan 16, 2026

Bills named in this filing 2

Lobbying activity 1

Health Issues

Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.